Home > Resources > Articles > Collaboration Is the X Factor in Making Precision Medicine a Success

Collaboration Is the X Factor in Making Precision Medicine a Success

JOHN WISE | November 11, 2019 | 273 views

Last year, the FDA approved 59 new molecular entities for the US market, the highest number ever approved in a single year. A key driver of this record level of approvals is the explosive growth of precision medicine. Since 2015, at least a fifth of all new drug approvals each year have been precision therapies and in 2018 they accounted for nearly half (42 per cent). These numbers are a result of significant, sustained investment from pharma companies and highlight just how central this approach will be in life science R&D going forward. Yet investment into drug development isn’t the only factor that will determine the success of the precision medicine market.

Spotlight

CVS Pharmacy

CVS Pharmacy is America’s leading retail pharmacy with more than 9,600 locations nationwide.

OTHER ARTICLES
PHARMA TECH

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | July 20, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
BUSINESS INSIGHTS

What are the advantages of PCD Pharma Company?

Article | June 30, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 7, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More
PHARMA TECH

Precision Medicine: New Horizons in Pharmaceuticals

Article | July 20, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
BUSINESS INSIGHTS

Why Is Diversity of Thought Essential for Developing a Winning Strategy?

Article | June 30, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

How Pharma Is Utilizing AI and Analytic Capabilities to Produce Positive Results

Article | July 7, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More
MORE ARTICLES

Spotlight

CVS Pharmacy

CVS Pharmacy is America’s leading retail pharmacy with more than 9,600 locations nationwide.

Related News

Pharma Titans Team To Tackle COVID-19

Precision Vaccinations | April 14, 2020

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mechanisms that offer fair access for people in all countries.’ This new collaboration marks a significant milestone in Sanofi’s and GSK’s ongoing contributions to help fight COVID-19. The companies have entered into a Material Transfer Agreement to enable them to start working together immediately. Definitive terms of the collaboration are expected to be finalized over the next few weeks.

Read More

Indiana University Employs Cloud Computing, AI for Precision Medicine

HITInfrastructure | October 10, 2019

IU is employing these technologies to target certain cancers, such as multiple myeloma, triple-negative breast cancer, and pediatric sarcomas, and chronic diseases, such as diabetes and Alzheimer’s, explained Peter Embi, MD, president and CEO of Regenstrief Institute, which is a medical research organization affiliated with IU and Purdue University. IU decided to partner with LifeOmic, which provides a secure cloud service for the long-term storage, retrieval, analysis, and clinical use of medical research data. IU has a 1.5 percent ownership stake in LifeOmic, which was founded by Don Brown, an IU alumnus. In addition, IU and other universities, through their Indiana Clinical Translational Sciences Institute (CTSI), are working with LifeOmic to provide the LIFE Extend app to enable Indiana residents to live a healthy lifestyle. CTSI is a research partnership among IU, Purdue University, and the University of Notre Dame. The LIFE Extend app includes the option for users to participate in the All IN for Health program, which links Indiana residents with opportunities to improve their health and participate in research and clinical studies. Indiana CTSI and LifeOmic have set a goal of engaging more than 100,000 residents in the All IN for Health program.

Read More

Precision Therapeutics’ Subsidiary, to Study Innovative Personalized Medicine Opportunities for Cancer Patients

Precision Therapeutics Inc. | April 11, 2019

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available through storing the patient’s live tumor tissue, have signed an agreement for Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform for a functional precision medicine study sponsored by SpeciCare. “SpeciCare is at the forefront of a renewed interest in functional precision medicine, which has been core to our personalized oncology approach for many years. We are excited to work with SpeciCare on their PIONEER initiative study, which will utilize Helomics’ core functional precision medicine technology of live tumor drug profiling assays (TruTumor™) and genomic profiling coupled with our AI-driven bioinformatics platform, D-CHIP,” commented Gerald J. Vardzel Jr., president of Helomics. “This collaboration further demonstrates the value of our CRO services and D-CHIP platform, both to generate revenue, and advance personalized medicine to improve patient treatment and outcomes.” Functional precision medicine goes beyond pure genomics to test live tumor tissue from the patient with a variety of approaches that interrogate how the tumor behaves, such as when challenged with potential therapies. Traditional genomics-only approaches often do not provide clinically actionable results outside of a handful of approved genomic biomarkers and associated drugs, limiting clinicians’ options for individualizing therapy.

Read More

Pharma Titans Team To Tackle COVID-19

Precision Vaccinations | April 14, 2020

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mechanisms that offer fair access for people in all countries.’ This new collaboration marks a significant milestone in Sanofi’s and GSK’s ongoing contributions to help fight COVID-19. The companies have entered into a Material Transfer Agreement to enable them to start working together immediately. Definitive terms of the collaboration are expected to be finalized over the next few weeks.

Read More

Indiana University Employs Cloud Computing, AI for Precision Medicine

HITInfrastructure | October 10, 2019

IU is employing these technologies to target certain cancers, such as multiple myeloma, triple-negative breast cancer, and pediatric sarcomas, and chronic diseases, such as diabetes and Alzheimer’s, explained Peter Embi, MD, president and CEO of Regenstrief Institute, which is a medical research organization affiliated with IU and Purdue University. IU decided to partner with LifeOmic, which provides a secure cloud service for the long-term storage, retrieval, analysis, and clinical use of medical research data. IU has a 1.5 percent ownership stake in LifeOmic, which was founded by Don Brown, an IU alumnus. In addition, IU and other universities, through their Indiana Clinical Translational Sciences Institute (CTSI), are working with LifeOmic to provide the LIFE Extend app to enable Indiana residents to live a healthy lifestyle. CTSI is a research partnership among IU, Purdue University, and the University of Notre Dame. The LIFE Extend app includes the option for users to participate in the All IN for Health program, which links Indiana residents with opportunities to improve their health and participate in research and clinical studies. Indiana CTSI and LifeOmic have set a goal of engaging more than 100,000 residents in the All IN for Health program.

Read More

Precision Therapeutics’ Subsidiary, to Study Innovative Personalized Medicine Opportunities for Cancer Patients

Precision Therapeutics Inc. | April 11, 2019

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available through storing the patient’s live tumor tissue, have signed an agreement for Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform for a functional precision medicine study sponsored by SpeciCare. “SpeciCare is at the forefront of a renewed interest in functional precision medicine, which has been core to our personalized oncology approach for many years. We are excited to work with SpeciCare on their PIONEER initiative study, which will utilize Helomics’ core functional precision medicine technology of live tumor drug profiling assays (TruTumor™) and genomic profiling coupled with our AI-driven bioinformatics platform, D-CHIP,” commented Gerald J. Vardzel Jr., president of Helomics. “This collaboration further demonstrates the value of our CRO services and D-CHIP platform, both to generate revenue, and advance personalized medicine to improve patient treatment and outcomes.” Functional precision medicine goes beyond pure genomics to test live tumor tissue from the patient with a variety of approaches that interrogate how the tumor behaves, such as when challenged with potential therapies. Traditional genomics-only approaches often do not provide clinically actionable results outside of a handful of approved genomic biomarkers and associated drugs, limiting clinicians’ options for individualizing therapy.

Read More

Events